European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.
Latest from John Shanahan
- Climate change or OMG event (Armstrong Economics, Martin Armstrong) USofA
- Solar minimum fastest decline in 10,000 years (Armstrong Economics, Martin Armstrong) USofA
- Looking at climate change debate (David Wojick, CFACT) USofA
- Disaster of CO2 reduction policies (Tim Ball) Canada
- Letter to Secretary DOE about coal and rare earth elements (Clinton Crackle) USofA